Full text
PDFPage 200
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
- Broom J., Heys S. D., Whiting P. H., Park K. G., Strachan A., Rothnie I., Franks C. R., Eremin O. Interleukin 2 therapy in cancer: identification of responders. Br J Cancer. 1992 Dec;66(6):1185–1187. doi: 10.1038/bjc.1992.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hamoudi W. H., Baum L. L. Anti-C-reactive protein inhibits the calcium-dependent stage of natural killer cell activation. J Immunol. 1991 Apr 15;146(8):2873–2878. [PubMed] [Google Scholar]
- Thijs L. G., Hack C. E., Strack van Schijndel R. J., Nuijens J. H., Wolbink G. J., Eerenberg-Belmer A. J., Van der Vall H., Wagstaff J. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol. 1990 Mar 15;144(6):2419–2424. [PubMed] [Google Scholar]
- Vachino G., Gelfand J. A., Atkins M. B., Tamerius J. D., Demchak P., Mier J. W. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood. 1991 Nov 15;78(10):2505–2513. [PubMed] [Google Scholar]